Detalhe da pesquisa
1.
Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancers.
Nature
; 566(7745): E11-E12, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30755741
2.
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.
N Engl J Med
; 385(8): 683-694, 2021 08 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-34407342
3.
HER kinase inhibition in patients with HER2- and HER3-mutant cancers.
Nature
; 554(7691): 189-194, 2018 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29420467
4.
Radiogenomic Associations Clear Cell Renal Cell Carcinoma: An Exploratory Study.
Oncology
; 101(6): 375-388, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37080171
5.
Ibrutinib combination therapy for advanced gastrointestinal and genitourinary tumours: results from a phase 1b/2 study.
BMC Cancer
; 23(1): 1056, 2023 Nov 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37919668
6.
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 23(9): 1133-1144, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36055304
7.
Management Trends and Outcomes of Patients Undergoing Radical Cystectomy for Urothelial Carcinoma of the Bladder: Evolution of the University of Southern California Experience over 3,347 Cases.
J Urol
; 207(2): 302-313, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34994657
8.
Integration of Liquid Biopsies in Clinical Management of Metastatic Prostate Cancer.
Curr Oncol Rep
; 24(10): 1287-1298, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35575959
9.
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV201): a multicentre, single-arm, phase 2 trial.
Lancet Oncol
; 22(6): 872-882, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33991512
10.
Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium - an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879.
Invest New Drugs
; 39(3): 812-820, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33409898
11.
Phase II trial of brentuximab vedotin in relapsed/refractory germ cell tumors.
Invest New Drugs
; 39(6): 1656-1663, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34031784
12.
Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA results.
Cancer
; 126(11): 2597-2606, 2020 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32208524
13.
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.
N Engl J Med
; 376(11): 1015-1026, 2017 03 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-28212060
14.
Safety and efficacy of CDX-014, an antibody-drug conjugate directed against T cell immunoglobulin mucin-1 in advanced renal cell carcinoma.
Invest New Drugs
; 38(6): 1807-1814, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32472319
15.
Influence of the facility caseload on the subsequent survival of men with localized prostate cancer undergoing radical prostatectomy.
Cancer
; 125(21): 3853-3863, 2019 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31398279
16.
Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer.
Cancer
; 125(23): 4172-4180, 2019 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31483485
17.
p53 nuclear accumulation as an early indicator of lethal prostate cancer.
Br J Cancer
; 121(7): 578-583, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31409910
18.
A phase II study of the orally administered negative enantiomer of gossypol (AT-101), a BH3 mimetic, in patients with advanced adrenal cortical carcinoma.
Invest New Drugs
; 37(4): 755-762, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31172443
19.
SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer.
World J Urol
; 37(1): 95-105, 2019 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-30238401
20.
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.
Lancet
; 389(10064): 67-76, 2017 01 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27939400